Share
In 2020 health tech finally had its day in the spotlight and made it into nearly every provider organization due to the coronavirus pandemic. However, as more and more Americans are vaccinated, some of that brick-and-mortar care will return.
Regardless, it s clear to see that digital health is here to stay. MobiHealthNews did our best to look into the crystal ball and made five predictions about what will happen in that space this year.
Telemedicine usage will even out, but will retain a number of new adopters
During the early days of the coronavirus pandemic we saw unprecedented use of telemedicine. In fact, a study in MMWR and Morbidity and Mortality Weekly reported that telehealth visits increased by 154% during the last week of March compared with the same period in 2019.
/PRNewswire/ If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this.
Share
The life science world has continued to deepen its interest in the digital space. While the mainstream life science news of the year was research on the coronavirus vaccine, when it came to digital the industries efforts were more varied. We saw new partnerships between pharma and digital health around topics such as respiration health, cardiovascular conditions and real-world data.
This year we’ve also seen a number of new digital therapeutics on the market. In fact, in April the FDA released new guidance on digital health devices for treating psychiatric disorders that waives several regulatory requirements – such as the need to submit a 510(k) premarket notification – for the duration of the COVID-19 emergency. During this period we saw both Pear Therapeutics and Akili Interactive Labs take advantage of this early release.
Wednesday’s Hot Stocks in Focus
Microvision Inc. (NASDAQ:MVIS) shares plummeted more than 26 percent this morning apparently after a series of tweets and retweets from short-seller Hindenburg Research on Tuesday. One of the tweets said, “We are short $MVIS. In a market gone mad, this $1.2 billion market cap corporate husk with almost no revenue or intellectual property value is a standout. It has risen 5,000% from lows this year on misguided retail euphoria over its LiDAR IP portfolio amid a broad EV bubble.” The Wednesday drop came just a day after MVIS share price skyrocketed more than 60 percent.
Novavax Inc. (NASDAQ:NVAX) shares closed higher today after an analyst at B.Riley reaffirmed a “Buy” rating for the Gaithersburg, Maryland-based vaccine development company, and set a price target of $223 for the stock. The price target set by analyst Mayank Mamtani is significantly higher than the stock’s current trading price of $127.65. Overall, most analysts are bullish
Oaktree Acquisition Corp. (NYSE: OAC)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
Oaktree Acquisition Corp. (NYSE: OAC) in connection with the company s proposed merger with privately-held telehealth company Hims, Inc. ( Hims ). Under the terms of the agreement, OAC will acquire Hims through a reverse merger that will result in Hims becoming a public company. If you own OAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
InterPrivate Acquisition Corp. (NYSE: IPV)